Assem Bakitzhanovna Uzakova

Mrs. Assem Bakitzhanovna Uzakova

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Assem Bakitzhanovna UzakovaAssem Bakitzhanovna Uzakova
Assem Bakitzhanovna Uzakova
EYElmira M. Yergaliyeva
Elmira M. Yergaliyeva
Azamat YerlanulyAzamat Yerlanuly
Azamat Yerlanuly
Zhazira MukatayevaZhazira Mukatayeva
Zhazira Mukatayeva
Background/Objectives: Advanced drug delivery systems (DDSs) are essential for targeted delivery, controlled release, and reduced systemic toxicity, but their clinical adoption is limited by biological barriers, manufacturing complexities, and cost. The aim of this systematic review is to critically evaluate the quantitative relationships between platform design, overcoming biological barriers, and clinical translation outcomes for DDS developed between 2016 and 2025. Methods: A comprehensive literature search was conducted in PubMed/MEDLINE, Scopus, and Web of Science (January 2016–April 2025) in accordance with the PRISMA 2020 guidelines. Included studies focused on experimental or clinical data for nanocarrier platforms (liposomes, lipid nanoparticles, polymer systems, biomimetic carriers, extracellular vesicles). Data on platform characteristics, interactions with barriers, pharmacokinetics, manufacturing, and clinical outcomes were extracted and synthesized in narrative form due to the significant methodological heterogeneity. Results: An analysis of 77 included studies confirms that successful clinical translation depends on matching the physicochemical properties of the carrier (size, surface chemistry, material) to specific biological barriers. Liposomes and lipid nanoparticles (LNPs) remain the most clinically validated platforms, exploiting the EPR effect and liver tropism, respectively. Key engineering solutions include stealth coatings, ligand-mediated targeting, and stimulus-responsive materials to overcome barriers such as mononuclear phagocyte system clearance, the blood–brain barrier, and mucosal barriers. Microfluidic and continuous manufacturing processes enable reproducibility, but scalability, cost, and immunogenicity (e.g., anti-PEG responses) remain key translational challenges. Engineered extracellular vesicles, biomimetic carriers, and 3D/4D-printed systems combined with AI-driven design demonstrate the potential for personalized, adaptive delivery. Conclusions: Cutting-edge DDSs have validated their clinical value, but realizing their full potential requires a holistic, patient-centered design approach integrating barrier-specific engineering, scalable manufacturing, and rigorous safety assessment from the earliest stages of development. Further progress will depend on standardizing methods for new platforms (e.g., extracellular vesicles), implementing digital and AI tools, and ensuring translational feasibility as a fundamental principle.

12 February 2021 in Molecules
Verified
Journal Article
Open access
PDF file
LKLyudmila Kayukova
Lyudmila Kayukova
AVAnna V. Vologzhanina
Anna V. Vologzhanina
KPKaldybay D. Praliyev
Kaldybay D. Praliyev
GDGulnur Dusembaeva
Gulnur Dusembaeva
GBGulnur Baitursynova
Gulnur Baitursynova
KAKydyrmolla Akatan
Kydyrmolla Akatan
The analysis of stability of biologically active compounds requires an accurate determination of their structure. We have found that 5-aryl-3-(2-aminoethyl)-1,2,4-oxadiazoles are generally unstable in the presence of acids and bases and are rearranged into the salts of spiropyrazolinium compounds. Hence, there is a significant probability that it is the rearranged products that should be attributed to biological activity and not the primarily screened 5-aryl-3-(2-aminoethyl)-1,2,4-oxadiazoles. A series of the 2-amino-8-oxa-1,5-diazaspiro[4.5]dec-1-en-5-ium (spiropyrazoline) benzoates and chloride was synthesized by Boulton–Katritzky rearrangement of 5-substituted phenyl-3-[2-(morpholin-1-yl)ethyl]-1,2,4-oxadiazoles and characterized using FT-IR and NMR spectroscopy and X-ray diffraction. Spiropyrazolylammonium chloride demonstrates in vitro antitubercular activity on DS (drug-sensitive) and MDR (multidrug-resistant) of MTB (M. tuberculosis) strains (1 and 2 µg/mL, accordingly) equal to the activity of the basic antitubercular drug rifampicin; spiropyrazoline benzoates exhibit an average antitubercular activity of 10–100 μg/mL on MTB strains. Molecular docking studies revealed a series of M. tuberculosis receptors with the energies of ligand–receptor complexes (−35.8–−42.8 kcal/mol) close to the value of intermolecular pairwise interactions of the same cation in the crystal of spiropyrazolylammonium chloride (−35.3 kcal/mol). However, only in complex with transcriptional repressor EthR2, both stereoisomers of the cation realize similar intermolecular interactions.

1 June 2018 in Chemistry of Heterocyclic Compounds
Verified
Journal Article
Closed access
PDF file
LKLyudmila Kayukova
Lyudmila Kayukova
Assem Bakitzhanovna UzakovaAssem Bakitzhanovna Uzakova
Assem Bakitzhanovna Uzakova
AVAnna V. Vologzhanina
Anna V. Vologzhanina
KAKydyrmolla Akatan
Kydyrmolla Akatan
ESEsbol Shaymardan
Esbol Shaymardan
SKSana Kabdrakhmanova
Sana Kabdrakhmanova

5 May 2019 in Pharmaceutical Chemistry Journal
Verified
Journal Article
Closed access
PDF file
LKL. A. Kayukova
L. A. Kayukova
Assem Bakitzhanovna UzakovaAssem Bakitzhanovna Uzakova
Assem Bakitzhanovna Uzakova
GBG. P. Baitursynova
G. P. Baitursynova
GDG. T. Dyusembaeva
G. T. Dyusembaeva
ZSZ. T. Shul’gau
Z. T. Shul’gau
SSSh. D. Sergazy
Sh. D. Sergazy

1 January 2018 in Research Journal of Pharmacy and Technology
Verified
Journal Article
Closed access
Assem Bakitzhanovna UzakovaAssem Bakitzhanovna Uzakova
Assem Bakitzhanovna Uzakova
LKLyudmila A. Kayukova
Lyudmila A. Kayukova
BPBladimir B. Poroikov
Bladimir B. Poroikov
KPKaldybai D. Praliev
Kaldybai D. Praliev

31 March 2025 in Veterinary World
Verified
Journal Article
Open access
LKLyudmila Kayukova
Lyudmila Kayukova
VBVenera Bismilda
Venera Bismilda
KTKairat Turgenbayev
Kairat Turgenbayev
Assem Bakitzhanovna UzakovaAssem Bakitzhanovna Uzakova
Assem Bakitzhanovna Uzakova
GBGulnur Baitursynova
Gulnur Baitursynova
AAAblay Auyezov
Ablay Auyezov
Background and Aim: Tuberculosis (TB) remains a significant global health challenge, with increasing incidences of drug-sensitive (DS) and multidrug-resistant (MDR) TB. In addition, Mycobacterium bovis-induced zoonotic TB (zTB) presents treatment difficulties due to its resistance to pyrazinamide and the prolonged treatment duration required. This study aims to evaluate the antitubercular potential of β-aminopropioamidoxime derivatives against DS and MDR Mycobacterium tuberculosis and M. bovis strains, and utilizing the SwissADME prognostic tool to predict the drug- and lead-likeness of the described compounds. Materials and Methods: Six β-aminopropioamidoxime derivatives were synthesized through O-aroylation of amidoxime followed by dehydration to form 1,2,4-oxadiazoles. The compounds were tested in vitro against DS, MDR M. tuberculosis, and M. bovis using Sotton’s liquid medium and subcultured on dense Lowenstein-Jensen medium. SwissADME was used to predict drug-likeness and pharmacokinetic properties. Results: The derivatives exhibited significant antitubercular activity, with in vitro efficacy 5–100 times greater than rifampicin. 1,2,4-oxadiazoles with para-bromo and meta-chloro substituents demonstrated the highest activity against DS and MDR M. tuberculosis, while O-para-toluoyl-β-(morpholin-1-yl)propioamidoxime salts (hydrochloride, oxalate and citrate) were 10 times more active against M. bovis. SwissADME analysis confirmed favorable pharmacokinetic properties, including high gastrointestinal absorption and drug-likeness, with lead-likeness identified in four compounds. Conclusion: The study presents β-aminopropioamidoxime derivatives as promising candidates for antitubercular therapy against both human and zTB. Their enhanced activity, oral bioavailability, and potential integration into new treatment regimens underscore their therapeutic relevance. Further in vivo studies are recommended to validate their efficacy and safety for clinical applications. Keywords: antitubercular agents, Mycobacterium bovis, Mycobacterium tuberculosis, SwissADME, tuberculosis, β-aminopropioamidoximes.